Abstract: Sustained-release abiraterone prodrug formulations, methods, and kits for parenteral administration to a subject having a sex hormone-dependent benign or malignant disorder such as prostate cancer, an androgen receptor driven cancer, a syndrome due to androgen excess, and/or a syndrome due to glucocorticoid excess such as hypercortisolemia.

Abstract: Sustained-release abiraterone prodrug formulations, methods, and kits for parenteral administration to a subject having a sex hormone-dependent benign or malignant disorder such as prostate cancer, an androgen receptor driven cancer, a syndrome due to androgen excess, and/or a syndrome due to glucocorticoid excess such as hypercortisolemia.

Abstract: A shared ledger operated by a group of network participants according to a set of consensus rules manages and resolves subrogation claims between a clamant and a defendant with arbitration. Evidence regarding the value of the subrogation claim is sent to the shared ledger by the parties to the subrogation claim such as sending data to a smart contract deployed on the shared ledger. The parties to the subrogation claim or entities that are not parties to the subrogation claim may broadcast data relating to fault to the blockchain. The data relating to fault may be evaluated by the parties or entities acting on the parties' behalf to determine fault. A fault determination may be broadcast to the blockchain based upon the analysis of the data relating to fault. Once the claim is resolved, arbitrator may release funds on the chain to the prevailing party or may accept confirmation that any payments have been made between the parties off-chain.

Abstract: Provided is a compound of formula (I) in which Ar1, R1, U, V, W, X, and p are as described herein. Also provided are methods of using a compound of formula (I), including a method of treating cancer, a method of treating a patient with cancer cells resistant to an anti-cancer agent, and a method of inhibiting lactate dehydrogenase A (LDHA) and/or lactate dehydrogenase B (LDHB) activity in a cell.

Abstract: The present application provides a beverage dispensing system. The beverage dispensing system may include a diluent line in communication with a diluent, a flow meter and a variable flow control module positioned on the diluent line, a number of syrup lines in communication with a number of syrups, and a fixed flow control module positioned on the syrup lines. The variable flow control module controls the flow rate of the diluent through the diluent line based upon the flow rate of one of the syrups through one of the syrup lines.

Abstract: The present application provides a beverage dispensing system. The beverage dispensing system may include a diluent line in communication with a diluent, a flow meter and a variable flow control module positioned on the diluent line, a number of syrup lines in communication with a number of syrups, and a fixed flow control module positioned on the syrup lines. The variable flow control module controls the flow rate of the diluent through the diluent line based upon the flow rate of one of the syrups through one of the syrup lines.

Abstract: Disclosed herein, inter alia, are compounds and methods for inhibiting Taspase1 and the treatment of cancer.

Abstract: Provided is a compound of formula (I) in which Ar1, R1, U, V, W, X, and p are as described herein. Also provided are methods of using a compound of formula (I), including a method of treating cancer, a method of treating a patient with cancer cells resistant to an anti-cancer agent, and a method of inhibiting lactate dehydrogenase A (LDHA) and/or lactate dehydrogenase B (LDHB) activity in a cell.

Abstract: An insert for use with a beverage dispenser includes a diffuser having an upstream end configured to receive the first base fluid, a downstream end with an outlet configured to dispense the first base fluid, and a center bore extending between the upstream end and the downstream end along an axis. A stem is disposed in the center bore of the diffuser and has a first end configured to receive a second base fluid and an opposite second end with an outlet configured to dispense the second base fluid. The outlet of the diffuser is upstream from the outlet of the stem such that the first base fluid dispensed from the outlet of the diffuser mixes with an additive fluid before the second base fluid dispensed from the outlet of the stem mixes with the additive fluid.

Abstract: The present invention is directed to methods of inhibiting p97 and compounds and compositions useful in such methods. Diseases and conditions the can be treated with the compounds and compositions of the invention include, but are not limited to, cancer and neurodegenerative disorders susceptible to treatment by inhibition of p97.

Abstract: A cartridge for dispensing a pre-measured buffering agent together with a medical fluid such as dental anesthetic. The cartridge includes a sharp piercing element at one end, a frangible barrier proximate the piercing element, and a traveling closure. The buffering solution is in a chamber between the barrier and the closure. When loaded into a syringe and subjected to operating pressures, the barrier is pierced, enabling the buffering solution to mix with the medical fluid. Continued pressure propels a desired, controlled mixture into a tissue of a patient. A dye may be included for visual confirmation of mixing. The invention may be regarded as the cartridge, a syringe having the cartridge, or a kit, with or without a syringe, or cartridges having closures of different types.

Abstract: The present application provides a beverage dispensing system for dispensing beverages with low solubility ingredients. The beverage dispensing system may include a sweetener flow, a first diluent flow, a low solubility ingredient premixing system for mixing a low solubility ingredient with a second diluent flow to create a mixed flow, and a nozzle to mix the sweetener flow, the first diluent flow, and the mixed flow.

Abstract: Provided is a compound of formula (I), in which Ar1, R1, U, V, W, X, and p are as described herein. Also provided are methods of using a compound of formula (I), including a method of treating cancer, a method of treating a patient with cancer cells resistant to an anti-cancer agent, and a method of inhibiting lactate dehydrogenase A (LDHA) and/or lactate dehydrogenase B (LDHB) activity in a cell.

Abstract: The present invention is directed to methods of inhibiting p97 and compounds and compositions useful in such methods. Diseases and conditions the can be treated with the compounds and compositions of the invention include, but are not limited to, cancer and neurodegenerative disorders susceptible to treatment by inhibition of p97.

Abstract: A cartridge for dispensing a pre-measured buffering agent together with a medical fluid such as dental anesthetic. The cartridge includes a sharp piercing element at one end, a frangible barrier proximate the piercing element, and a traveling closure. The buffering solution is in a chamber between the barrier and the closure. When loaded into a syringe and subjected to operating pressures, the barrier is pierced, enabling the buffering solution to mix with the medical fluid. Continued pressure propels a desired, controlled mixture into a tissue of a patient. A dye may be included for visual confirmation of mixing. The invention may be regarded as the cartridge, a syringe having the cartridge, or a kit, with or without a syringe, or cartridges having closures of different types.

Abstract: Provided is a compound of formula (I)[Formula (I) should be inserted here], in which Ar1, R1, U, V, W, X, and p are as described herein. Also provided are methods of using a compound of formula (I), including a method of treating cancer, a method of treating a patient with cancer cells resistant to an anti-cancer agent, and a method of inhibiting lactate dehydrogenase A (LDHA) and/or lactate dehydrogenase B (LDHB) activity in a cell.

Abstract: Provided is a compound of formula (I) in which Ar1, R1, U, V, W, X, and p are as described herein. Also provided are methods of using a compound of formula (I), including a method of treating cancer, a method of treating a patient with cancer cells resistant to an anti-cancer agent, and a method of inhibiting lactate dehydrogenase A (LDHA) and/or lactate dehydrogenase B (LDHB) activity in a cell.

Abstract: The disclosure provides a compound of the formula (II) and pharmaceutically acceptable salts thereof. The variables, e.g. n, R, R3, R10, X, Y, and Z are defined herein. These compounds act as lactate dehydrogenase inhibitors and are useful for treating cancer and fibrosis. The compounds may be particularly useful for treating forms of cancer in which a metabolic switch from oxidative phosphorylation to glycolysis has occurred. The disclosure also provides pharmaceutical compositions containing a compound of this formula and method for treating patients having cancer, fibrosis, or other conditions in which a metabolic switch from oxidative phosphorylation to glycolysis has occurred.

Abstract: Systems and methods are disclosed herein that include providing a beverage dispensing machine with a cleaning system comprising a first water branch and a second water branch connected in fluid communication with a three-way valve, a cleaning supply connected in fluid communication with the second water branch via a pump, and a nozzle. The three-way valve may be operated in a “dispensing mode” to provide a flow of at least one of water and carbonated water through the first water branch and a flowpath of the three-way valve to the nozzle, and operated in a “cleaning mode” to provide a flow of a cleaner, and optionally a flow of at least one of water and carbonated water, through the second water branch and a secondary flowpath of the three-way valve to the nozzle to clean the nozzle and/or a drain of the beverage dispensing machine.

Abstract: Systems and methods are disclosed herein that include providing a beverage dispensing machine with a cleaning system comprising a first water branch and a second water branch connected in fluid communication with a three-way valve, a cleaning supply connected in fluid communication with the second water branch via a pump, and a nozzle. The three-way valve may be operated in a “dispensing mode” to provide a flow of at least one of water and carbonated water through the first water branch and a flowpath of the three-way valve to the nozzle, and operated in a “cleaning mode” to provide a flow of a cleaner, and optionally a flow of at least one of water and carbonated water, through the second water branch and a secondary flowpath of the three-way valve to the nozzle to clean the nozzle and/or a drain of the beverage dispensing machine.